Skip to main content

Market Overview

Goldman Removes Hologic From Conviction Buy List, Maintains Buy


Goldman Sachs’ Isaac Ro believes that with the early adoption curve for Hologic, Inc. (NASDAQ: HOLX)'s tomosynthesis product having played out, “the upside case will rest on the balance of the company’s portfolio,” where expectations are still low.

Ro maintained a Buy rating on Hologic, with a price target of $45, while removing the company from Goldman Sachs’ Americas Conviction Buy List.

The analyst pointed out that since the stock was added to the America’s Conviction Buy List in December 2014, it has appreciated 29 percent, as compared to the 3 percent rise in the S&P 500.

Positive Outlook

Ro also explained the Buy rating has been maintained due to the view that “(1) consensus underestimates the durability of HOLX’s franchise outside of Breast Health and (2) improving balance sheet flexibility will further augment HOLX’s core growth rate.”

The analyst pointed out that new products, including the Affirm biopsy and Panther Fusion, were likely to enhance Hologic’s organic growth rate in FY17, even as tomosynthesis adoption decelerates.

“Management has a stated desire to pursue tuck-in M&A, which we expect should drive additional upside in the coming quarters,” Ro added.

Latest Ratings for HOLX

Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs Isaac RoAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas

Latest Ratings

ENTGUBSInitiates Coverage On120.0
RBAOTR GlobalDowngrades
TTDVertical ResearchUpgrades
DCredit SuisseMaintains90.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at